|
|||||
|
|
A first‐in‐human study of DS‐1040, an inhibitor of the activated form of thrombin‐activatable fibrinolysis inhibitor,in healthy subjects |
|
| Authors: | J. Zhou J. Kochan O. Yin V. Warren C. Zamora G. Atiee J. Pav Y. Orihashi V. Vashi V. Dishy |
| Affiliation: | 1. Daiichi Sankyo Pharma Development, Edison, NJ, USA;2. Worldwide Clinical Trials, San Antonio, TX, USA;3. Daiichi Sankyo Development Ltd, Gerrards Cross, UK |
| Abstract: | |
| Keywords: | fibrinolysis pharmacodynamics pharmacokinetics thrombin‐activatable fibrinolysis inhibitor thrombosis |